Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity
US8940702B2 · kind B2 · utility
0Cited by
1References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 26, 2010 |
| Grant date | Jan 27, 2015 |
| Priority date | — |
| Expiry date | Aug 6, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention pertains to PF4 muteins which comprise a substitution at position 67, e.g. a L67H substitution, compared to the sequence of the wild-type PF4 protein. Such PF4 muteins exhibit an increased anti-angiogenie activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.